Anavex Life Sciences Corp (AVXL)

[Investor2014]

Yes an in the 10-Q Anavex does not write this fact from the most recent 10-K. Form 10-K for the "Period End Date September 30, 2020"

U.S. patents related to ANAVEX®2-73 are directed to a dosage form comprising certain doses of ANAVEX®2-73 and donepezil, and the coverage is limited to the United States only. We may not be able to obtain patent protection for ANAVEX®2-73 as a single drug or in other jurisdictions.

Which is in regard to this first patent quoted from your post:

We own one issued U.S. patent entitled “ANAVEX®2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection” claims a composition of matter of ANAVEX®2-73 directed to a novel and synergistic neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This patent is expected to expire in June 2034, absent any patent term extension for regulatory delays.

The issue here is that this patent is the only one claiming the form of the A2-73 compound currently being trialled with an ordinary dosing scheme for approval and it can only be enforced in the United States.

Anavex have no longer patent protection to replace the original Vamvakides patent on A2-73 in it current form for standalone treatment.

As Anavex must point out in 10-K this is a risk, but one as I have said they can likely successfully navigate.

Not BS, just fact!